NRx Pharmaceuticals amends 8-K to provide acquired Dura Medical's FY2024 financials

NRX Pharmaceuticals, Inc.

Acquisition of Dura Medical closed September 8, 2025; this amendment provides required financials.
Dura Medical FY2024: net patient revenue $3.26M, net income $505K, total assets $1.37M.
Dura Medical for six months ended June 30, 2025 (unaudited) also provided.
Pro forma combined financials filed; reflects impact of acquisition on NRx statements.
Audited by Weinberg & Company; no material adjustments noted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.